PMID- 9769301
OWN - NLM
STAT- MEDLINE
DCOM- 19981103
LR  - 20220408
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 98
IP  - 15
DP  - 1998 Oct 13
TI  - Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary 
      syndromes and stable coronary artery disease.
PG  - 1487-94
AB  - BACKGROUND: The association between oxidative modifications of LDL and coronary 
      artery disease (CAD) is suspected but not established. Therefore, the association 
      between plasma levels of oxidized LDL and malondialdehyde (MDA)-modified LDL and 
      acute coronary syndromes and stable CAD was investigated. METHODS AND RESULTS: 
      The study population contained 63 patients with acute coronary syndromes (45 with 
      acute myocardial infarction and 18 with unstable angina pectoris), 35 
      nontransplanted patients with angiographically confirmed stable angina, 28 heart 
      transplant patients with posttransplant CAD, 79 heart transplant patients without 
      CAD, and 65 control subjects. After correction for age, sex, and LDL and HDL 
      cholesterol, plasma levels of oxidized LDL and MDA-modified LDL were 
      significantly higher in patients with CAD than in individuals without CAD 
      (r2=0.57 and r2=0.26, respectively; both P=0.0001). Plasma levels of MDA-modified 
      LDL were significantly higher in patients with acute coronary syndromes than in 
      individuals with stable CAD (r2=0.65; P=0.0001) and were associated with 
      increased levels of troponin I and C-reactive protein (r2=0.39 and r2=0.34, 
      respectively; both P=0.0001). Plasma levels of oxidized LDL were not associated 
      with increased levels of troponin I and C-reactive protein (r2=0.089 and 
      r2=0.063, respectively). CONCLUSIONS: Elevated plasma levels of oxidized LDL are 
      associated with CAD. Elevated plasma levels of MDA-modified LDL suggest plaque 
      instability and may be useful for the identification of patients with acute 
      coronary syndromes.
FAU - Holvoet, P
AU  - Holvoet P
AD  - Center for Molecular and Vascular Biology, University of Leuven, Belgium 
      paul.holvoet@med.kuleuven.ag.be
FAU - Vanhaecke, J
AU  - Vanhaecke J
FAU - Janssens, S
AU  - Janssens S
FAU - Van de Werf, F
AU  - Van de Werf F
FAU - Collen, D
AU  - Collen D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Troponin I)
RN  - 0 (fibrin fragment D)
RN  - 0 (oxidized low density lipoprotein)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Aged
MH  - Angina Pectoris/*metabolism
MH  - Arteries/pathology
MH  - C-Reactive Protein/analysis
MH  - Coronary Disease/*metabolism
MH  - Coronary Vessels/pathology
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/analysis
MH  - Heart Transplantation
MH  - Humans
MH  - Lipoproteins, LDL/blood/*metabolism
MH  - Male
MH  - Malondialdehyde/blood/*metabolism
MH  - Middle Aged
MH  - Myocardial Infarction/*metabolism
MH  - Oxidation-Reduction
MH  - Regression Analysis
MH  - Troponin I/blood
EDAT- 1998/10/14 00:00
MHDA- 1998/10/14 00:01
CRDT- 1998/10/14 00:00
PHST- 1998/10/14 00:00 [pubmed]
PHST- 1998/10/14 00:01 [medline]
PHST- 1998/10/14 00:00 [entrez]
AID - 10.1161/01.cir.98.15.1487 [doi]
PST - ppublish
SO  - Circulation. 1998 Oct 13;98(15):1487-94. doi: 10.1161/01.cir.98.15.1487.